Here's What You May Have Missed About Baxter International(BAX)

By Naomi Wentworth • Saturday, August 16 15:23 • Permanent Link

More and more people are talking about Baxter International over the last few weeks. Is it worth buying the Medical Instruments & Supplies stock at a price of $24.18? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Baxter International has moved -33.7% over the last year, and the S&P 500 logged a change of 15.0%
BAX has an average analyst rating of hold and is -17.64% away from its mean target price of $29.36 per share
Its trailing earnings per share (EPS) is $-0.48
Baxter International has a trailing 12 month Price to Earnings (P/E) ratio of -50.4 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $2.88 and its forward P/E ratio is 8.4
The company has a Price to Book (P/B) ratio of 1.7 in contrast to the S&P 500's average ratio of 4.74
Baxter International is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $1.71 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.